Effect Of Gonadotropin-releasing Hormone Agonist And Human Chorionic Gonadotropin In Gonadotropin-releasing Hormone Antagonist Protocol On Pregnancy Outcome

Objective: To explore the effect of gonadotropin-releasing hormone agonist(GnRHa)and human chorionic gonadotropin(h CG)as triggers in GnRH antagonist protocol on embryo quality and pregnancy outcomes.Methods: In this prospective study,224 women who underwent GnRH antagonist protocol and in vitro fertilization/intracytoplasmic sperm injection were included.The patients were divided into two groups:group A,wherein patients were administered 0.2mg GnRHa,and group B,wherein patients were administered 250 μg recombinant h CG.Both groups underwent fresh cycles and freeze-all cycles.The laboratory and clinical parameters from the two groups were evaluated and compared.Results: The number of embryos that underwent 2 pronuclear(2PN)and 2PN cleavage in group A was significantly higher than that in group B(P<0.05);there were no significant difference in 2PN rate,2PN cleavage rate,and the numbers of transplantable embryos and high-quality embryos(P>0.05).The number of embryos that underwent cleavage for blastocyst formation,the number of blastocysts,and the rate of blastocyst formation were significantly higher in group A than those in group B(P<0.05).The biochemical pregnancy,clinical pregnancy,and live birth rates were higher and the miscarriage rate was lower in group A than in group B,but the differences were not statistically significant(P>0.05).Conclusion: GnRHa can increase the rate of blastocyst formation without reducing the biochemical pregnancy,clinical pregnancy,and live birth rates.Compared with recombinant h CG,GnRHa can better ensure the safety of patients.GnRHa may be used as a clinical first-line trigger drug.